tiprankstipranks
Advertisement
Advertisement

STRO Stock Latest News

Analyst Reaffirms Buy on Sutro Biopharma as Advancing ADC Platform and Upcoming STRO-004 Data Drive Upside Optionality
RatingsAnalyst Reaffirms Buy on Sutro Biopharma as Advancing ADC Platform and Upcoming STRO-004 Data Drive Upside Optionality
3d ago
STRO
Sutro Biopharma initiated with an Overweight at Barclays
PremiumThe Fly
Sutro Biopharma initiated with an Overweight at Barclays
7d ago
STRO
Analyst Reiterates Buy on Sutro Biopharma, Maintains $54 Price Target on Differentiated ADC Platform and Pipeline Progress
PremiumRatings
Analyst Reiterates Buy on Sutro Biopharma, Maintains $54 Price Target on Differentiated ADC Platform and Pipeline Progress
9d ago
STRO
Sutro Biopharma price target raised to $10 from $9 at BofA
PremiumThe Fly
Sutro Biopharma price target raised to $10 from $9 at BofA
13d ago
STRO
Sutro Biopharma: Buy Rating on Strong ADC Execution, Cash Runway Into 2028, and Multiple 2026 Catalysts
PremiumRatings
Sutro Biopharma: Buy Rating on Strong ADC Execution, Cash Runway Into 2028, and Multiple 2026 Catalysts
20d ago
STRO
Wedbush upgrades Sutro Biopharma to Outperform, raises price target to $60
PremiumThe FlyWedbush upgrades Sutro Biopharma to Outperform, raises price target to $60
20d ago
STRO
Sutro Biopharma upgraded to Outperform from Neutral at Wedbush
Premium
The Fly
Sutro Biopharma upgraded to Outperform from Neutral at Wedbush
20d ago
STRO
Sutro Biopharma price target raised to $50 from $28 at H.C. Wainwright
Premium
The Fly
Sutro Biopharma price target raised to $50 from $28 at H.C. Wainwright
20d ago
STRO
Sutro Biopharma price target raised to $43 from $38 at Leerink
PremiumThe Fly
Sutro Biopharma price target raised to $43 from $38 at Leerink
20d ago
STRO
Analyst Reiterates Buy on Sutro Biopharma, Citing STRO-004 Phase I Readout and Broader ADC Platform Potential
PremiumRatings
Analyst Reiterates Buy on Sutro Biopharma, Citing STRO-004 Phase I Readout and Broader ADC Platform Potential
20d ago
STRO
Sutro Biopharma reports Q1 EPS ($2.94), consensus ($3.21)
PremiumThe Fly
Sutro Biopharma reports Q1 EPS ($2.94), consensus ($3.21)
20d ago
STRO
STRO Earnings this Week: How Will it Perform?
PremiumPre-Earnings
STRO Earnings this Week: How Will it Perform?
24d ago
STRO
Meta downgraded, Qualcomm upgraded: Wall Street’s top analyst calls
PremiumThe FlyMeta downgraded, Qualcomm upgraded: Wall Street’s top analyst calls
1M ago
MG
RS
Sutro Biopharma initiated with an Outperform at Mizuho
Premium
The Fly
Sutro Biopharma initiated with an Outperform at Mizuho
1M ago
STRO
Sutro Biopharma price target raised to $41 from $35 at Citizens
Premium
The Fly
Sutro Biopharma price target raised to $41 from $35 at Citizens
1M ago
STRO
Sutro Biopharma presents preclinical data across its pipeline of ADCs
PremiumThe Fly
Sutro Biopharma presents preclinical data across its pipeline of ADCs
2M ago
STRO
Sutro Biopharma price target raised to $35 from $23 at Citizens
PremiumThe Fly
Sutro Biopharma price target raised to $35 from $23 at Citizens
2M ago
STRO
Sutro Biopharma management to meet with Citizens
PremiumThe Fly
Sutro Biopharma management to meet with Citizens
2M ago
STRO
Leerink says Tubulis deal highlights value of ADC platforms like Sutro’s
PremiumThe Fly
Leerink says Tubulis deal highlights value of ADC platforms like Sutro’s
2M ago
GILD
IMNM
Arm downgraded, Arista Networks upgraded: Wall Street’s top analyst calls
PremiumThe FlyArm downgraded, Arista Networks upgraded: Wall Street’s top analyst calls
2M ago
ARM
WAL
Sutro Biopharma initiated with an Outperform at Leerink
Premium
The Fly
Sutro Biopharma initiated with an Outperform at Leerink
2M ago
STRO
Sutro Biopharma price target raised to $55 from $51 at Deutsche Bank
Premium
The Fly
Sutro Biopharma price target raised to $55 from $51 at Deutsche Bank
2M ago
STRO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >